Osavampator for Depression: What It Is, How It Works, and Where It Stands (November 2026)

Written by
Justin Ray
Published on
June 17, 2025
 • 
10
min read
Last reviewed
November 7, 2026
by
Justin Ray
A computer generated image of a human brain

Article Overview

For decades, major depressive disorder (MDD) has been treated primarily with medications that influence monoamine neurotransmitters: serotonin, norepinephrine, and dopamine. While SSRIs, SNRIs, and atypical antipsychotics have helped many, a significant portion of people with MDD continue to experience partial or inadequate response. That gap has driven the search for adjunctive therapies with genuinely different mechanisms, and few investigational agents have drawn as much attention as osavampator (formerly NBI-1065845, originally Takeda's TAK-653).

This article was first published in June 2025 and has been updated to reflect where the drug stands as of November 1, 2026. Osavampator remains investigational: it is not FDA-approved and is not available outside clinical trials.

Where osavampator stands (November 2026)

  • Status: Investigational, in Phase 3. No New Drug Application has been filed and no approval decision is pending.
  • Who is developing it: Neurocrine Biosciences holds an exclusive license from Takeda Pharmaceutical for all indications worldwide except Japan.
  • Phase 2 (SAVITRI, NCT05203341): Completed. Positive topline results announced April 23, 2024; fuller data presented at Psych Congress in September 2025, where the poster received the meeting's 2025 Poster Award.
  • Phase 3 program: Initiated January 2025. ClinicalTrials.gov lists four registered studies, all recruiting as of their most recent updates: two placebo-controlled efficacy trials of adjunctive osavampator in adults with MDD (NCT06786624, started January 22, 2025, and NCT06963021, started May 30, 2025; about 200 participants each; primary endpoint is change in MADRS score at Day 56; estimated primary completion July 2027), a 52-week open-label safety study (NCT06966401, about 850 participants), and a maintenance-of-effect, relapse-prevention study (NCT07196501, about 550 participants, started August 2025). Neurocrine's September 2025 release described five active Phase 3 studies.
  • Expected results: In its second-quarter 2026 earnings release (July 30, 2026), Neurocrine listed "Phase 3 readouts for osavampator in major depressive disorder" among its 2027 milestones. No month or quarter has been given. Earlier versions of this article cited "late 2026 or early 2027"; 2027 is now the company's guidance. In its third-quarter results on November 2, 2026, Neurocrine again listed Phase 3 readouts for osavampator among its 2027 milestones, with management pointing to the second half of 2027 on the earnings call, and announced an R&D Day for December 15, 2026, where more detail may follow.
  • Dose being studied: 1 mg once daily by mouth, the lower of the two Phase 2 doses, chosen after an exposure-response analysis.

What osavampator is (and is not)

Osavampator is an oral, once-daily, selective positive allosteric modulator (PAM) of the AMPA receptor, one of the main receptors for glutamate, the brain's principal excitatory neurotransmitter. It is being developed as an adjunctive treatment, meaning it would be added to an existing antidepressant rather than replacing it, for adults with MDD who have not responded adequately to that antidepressant.

It is useful to be equally clear about what it is not:

  • Not a psychedelic. Osavampator is a selective AMPA-receptor modulator, not a serotonergic drug; classic psychedelics work through the serotonin 2A receptor, which is not its target. It does not produce hallucinations or altered perception, and no dissociation was reported in its trials. It is taken daily at home like a conventional medication, not in a monitored session.
  • Not an SSRI, SNRI, or antipsychotic. It does not block serotonin or norepinephrine reuptake and does not act on dopamine receptors, which is why it is described as a non-monoamine antidepressant.
  • Not ketamine or esketamine. Ketamine and Spravato (esketamine) block NMDA receptors and are thought to increase AMPA signaling indirectly, which is accompanied by dissociation and sedation. Osavampator works on the AMPA receptor directly and, in trials to date, without those effects.
  • Not approved and not available. It cannot be prescribed, compounded, or purchased. The only way to receive it is through enrollment in a clinical trial.

How does osavampator work?

Glutamate is the chemical the brain uses for most fast, excitatory communication between neurons. When glutamate binds an AMPA receptor, the receptor opens briefly and the receiving neuron becomes more likely to fire. A positive allosteric modulator does not open the receptor on its own; it binds to a separate site and amplifies the response when the brain's own glutamate arrives. That distinction matters: a PAM strengthens signaling that is already happening rather than forcing activity everywhere, which is one reason the approach is expected to carry less risk of overstimulation than a direct agonist.

Why would that help depression? Converging research on ketamine and related compounds suggests that rapid antidepressant effects depend on a burst of AMPA-receptor signaling that triggers release of brain-derived neurotrophic factor (BDNF), activates growth pathways such as mTOR, and restores synaptic connections in prefrontal and limbic circuits that are thinned out in chronic depression. Ketamine reaches that AMPA step indirectly by blocking NMDA receptors. Osavampator is designed to engage it directly, potentially preserving the neuroplasticity-promoting effect without the dissociation, blood-pressure changes, and abuse potential that come with NMDA blockade. This is the mechanistic hypothesis; whether it fully explains the clinical results will be clearer when the Phase 3 data arrive.

In contrast to dopamine partial agonists such as Rexulti and Abilify, which modulate dopaminergic tone and can cause restlessness and motor side effects, osavampator has no direct dopaminergic activity. Caplyta works through a broader mechanism, touching serotonin, dopamine, and glutamate pathways. Osavampator's AMPA-selective activity is the most targeted glutamatergic approach among the adjunctive options discussed here.

What the Phase 2 SAVITRI trial showed

SAVITRI was a randomized, double-blind, placebo-controlled, dose-finding study in 183 adults ages 18 to 65 with MDD who had an inadequate response (less than 50% improvement) to their current antidepressant. Participants were randomized 2:1:1 to placebo (n=91), osavampator 1 mg (n=45), or osavampator 3 mg (n=47), taken once daily on top of their existing antidepressant for eight weeks; 88% completed treatment.

  • Primary endpoint (MADRS change at Day 28): Osavampator 1 mg reduced MADRS scores by 4.3 points more than placebo (95% CI −7.8 to −0.8; p=0.0159).
  • Day 56: The advantage for 1 mg widened to 6.9 points (95% CI −11.2 to −2.6; p=0.0018), corresponding to an effect size of 0.73. The April 2024 topline analysis reported the Day 56 difference as 7.5 points (p=0.0016); the smaller figure comes from the updated analysis presented in 2025.
  • Response and remission: At Day 56, participants on 1 mg were significantly more likely than those on placebo to achieve response (at least 50% MADRS improvement) and remission (MADRS of 10 or less).
  • The 3 mg dose did not separate from placebo. Differences of about 3.0 points at Day 28 (p=0.0873) and 3.6 points at Day 56 (p=0.1082) were described as a favorable trend but were not statistically significant. The absence of a clean dose-response relationship is the most common caution raised about these data, and it is why Phase 3 is testing 1 mg only.

Context for the numbers: an effect size of 0.73 at eight weeks would be large for an adjunctive antidepressant trial if it holds up. But SAVITRI was a Phase 2 study with fewer than 50 people per active arm, and Phase 2 effect sizes routinely shrink in larger confirmatory trials. The two Phase 3 efficacy studies use Day 56 as the primary endpoint, so the field will get a direct test of the eight-week result.

Osavampator side effects reported so far

Across SAVITRI, osavampator was well tolerated at both doses. There were no deaths, no serious adverse events, and no adverse events of special interest. Rates of any treatment-emergent adverse event were 42.9% on placebo, 55.6% on 1 mg, and 44.7% on 3 mg. The individual side effects reported were:

Adverse eventPlacebo (n=91)Osavampator 1 mg (n=45)Osavampator 3 mg (n=47)
Headache8.8%11.1%4.3%
Nasopharyngitis (common cold)5.5%4.4%6.4%
Insomnia2.2%2.2%6.4%
Somnolence3.3%6.7%0%
Nausea5.5%2.2%0%
Dizziness5.5%0%0%

Notably, the problems that limit many existing adjuncts, dissociation, akathisia or restlessness, weight gain or metabolic changes, and sexual dysfunction, did not appear among the reported adverse events. Two caveats apply. First, these are eight-week data in fewer than 100 people on active drug; rare or slow-developing effects would not be visible. Second, the 52-week open-label safety study now under way is designed specifically to answer the long-term tolerability question, and it will not finish until 2029.

Who osavampator may suit, if it is approved

The Phase 3 efficacy studies enroll adults 18 and older with a primary diagnosis of recurrent moderate-to-severe MDD or persistent depressive disorder, a HAM-D17 score of 22 or higher, and at least eight weeks on a stable dose of an oral antidepressant that has not worked well enough. People whose primary problem in the past year was a different psychiatric disorder, who are at imminent suicide risk, or who failed electroconvulsive therapy in the current episode are excluded. If approved, the realistic target population is therefore the client who has had a partial response to one or more antidepressants and needs something added, which is the same space occupied today by Caplyta, Rexulti, Abilify, and, for treatment-resistant cases, Spravato.

It has not been studied in bipolar depression, in adolescents, or as a stand-alone treatment, and there is no information yet on use in pregnancy or alongside other glutamatergic drugs.

How osavampator compares with today's adjunctive options

Comparing across different trials is imprecise, since study populations and placebo responses differ, so the numbers below are context rather than a head-to-head ranking.

Caplyta (lumateperone). FDA-approved as an adjunct to antidepressants for MDD on November 6, 2025, after two pivotal trials showed MADRS improvements of 4.9 points (effect size 0.61) and 4.5 points (effect size 0.56) over placebo at six weeks, with separation as early as one to two weeks. Weight gain, metabolic changes, and akathisia were similar to placebo, and extrapyramidal symptoms were low. Caplyta is the newest approved comparator and the one whose tolerability profile most resembles what osavampator is aiming for.

Rexulti (brexpiprazole) and Abilify (aripiprazole). These dopamine partial agonists remain the most widely prescribed adjuncts. In their six-week pivotal trials each produced roughly a 2- to 4-point MADRS advantage over placebo: brexpiprazole 2 mg separated by 3.2 points and 3 mg by 2.0 points (the 1 mg dose did not reach significance), and adjunctive aripiprazole by 2.8 to 3.7 points across its three registration studies (Thase et al., 2015; Marcus et al., 2008; Berman et al., 2009). Those are small-to-moderate differences. In practice both can be limited by akathisia, restlessness, weight gain, and, with brexpiprazole, insomnia.

Auvelity (dextromethorphan-bupropion). Approved in August 2022 for major depressive disorder in adults, Auvelity is the other oral non-monoamine option clients frequently ask about. It works upstream of osavampator in the same glutamate pathway, as an uncompetitive NMDA-receptor antagonist and sigma-1 agonist, rather than on the AMPA receptor directly. Its pivotal trials studied it on its own rather than as an add-on, so it is not a like-for-like comparator for adjunctive data, although it is commonly combined with other antidepressants in practice.

Spravato (esketamine). An intranasal NMDA antagonist administered under observation in a certified clinic, approved for treatment-resistant depression. It is the most direct mechanistic cousin of osavampator and the option with the strongest evidence for rapid effect in clients who have failed multiple antidepressants, but it requires two-hour monitored visits and produces transient dissociation and blood-pressure elevation.

If the Phase 3 results replicate SAVITRI, osavampator's combination of oral daily dosing, a glutamatergic mechanism, and the absence of dopaminergic, sedative, and metabolic side effects would make it a distinctive addition. If they do not, the field will have learned something important about how far the AMPA hypothesis extends beyond ketamine.

Frequently asked questions about osavampator

Is osavampator a psychedelic?

No. Osavampator is an AMPA-receptor positive allosteric modulator, not a serotonergic drug like psilocybin or LSD. It does not alter perception or produce hallucinations, and no dissociation was reported in its clinical trials. It is a daily oral pill taken at home, not a drug given in a supervised psychedelic session.

Is osavampator FDA approved?

No. As of November 2026 osavampator is in Phase 3 clinical trials. No application for approval has been submitted, and the company developing it has said the Phase 3 results are expected in 2027. It cannot be prescribed.

When will osavampator be available?

Not before the Phase 3 studies read out, which Neurocrine currently expects in 2027. If those studies are positive, the company would still need to file a New Drug Application and complete an FDA review before the drug could be prescribed, so availability would come some time after the readout. Neurocrine has not given a launch date, and this article will be updated when it does.

What are the side effects of osavampator?

In the eight-week Phase 2 trial, the only side effects reported in more than 5% of people were headache and the common cold, at rates similar to placebo. There were no serious adverse events, and no dissociation, akathisia, weight gain, or sexual side effects were reported. Long-term safety is still being studied.

Is osavampator the same as ketamine or Spravato?

No, though they are related. Ketamine and Spravato block NMDA receptors and are thought to boost AMPA signaling indirectly, which comes with dissociation and sedation. Osavampator enhances AMPA signaling directly, and those effects were not reported in its trials. Spravato is approved and available now; osavampator is not.

Can I join an osavampator clinical trial?

Possibly. The Phase 3 program is recruiting adults 18 and older with moderate-to-severe depression who have been on a stable antidepressant for at least eight weeks without enough improvement. Study sites and eligibility details are listed on ClinicalTrials.gov under NCT06786624, NCT06963021, NCT06966401, and NCT07196501. Participation is a decision to make with your treating provider.

Talk to a provider

When depression has not responded to two or more antidepressants, there are effective options available today while the next generation of treatments is studied. Learn how we approach treatment-resistant depression in Chesapeake, including SPRAVATO® treatment through TRIP, or schedule a consultation to review your current regimen. This article is educational and is not a substitute for individualized medical advice. If you are in crisis or thinking about harming yourself, call or text 988 to reach the Suicide and Crisis Lifeline.

Sources

Neurocrine Biosciences. (2024, April 23). Neurocrine Biosciences reports positive Phase 2 data for NBI-1065845 in adults with major depressive disorder [Press release].

Neurocrine Biosciences. (2025, January 28). Neurocrine Biosciences announces initiation of Phase 3 registrational program for osavampator as an adjunctive therapy for the treatment of major depressive disorder in adults [Press release].

Neurocrine Biosciences. (2025, September 22). Neurocrine Biosciences presents positive new data from Phase 2 study of osavampator in adults with major depressive disorder [Press release].

Singh, J. B., et al. (2025). Osavampator (NBI-1065845/TAK-653) in adults with major depressive disorder: Results from the Phase 2 SAVITRI study [Poster #33]. Psych Congress 2025.

Neurocrine Biosciences. (2026, July 30). Neurocrine Biosciences reports second-quarter 2026 financial results [Press release; Form 8-K exhibit].

ClinicalTrials.gov records NCT05203341, NCT06786624, NCT06963021, NCT06966401, and NCT07196501 (accessed October 24, 2026).

Thase, M. E., et al. (2015). Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder. Journal of Clinical Psychiatry, 76(9), 1224–1231; and Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants. Journal of Clinical Psychiatry, 76(9), 1232–1240.

Marcus, R. N., et al. (2008). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 28(2), 156–165. Berman, R. M., et al. (2009). Aripiprazole augmentation in major depressive disorder. CNS Spectrums, 14(4), 197–206.

Johnson & Johnson. (2025, November 6). FDA approval of CAPLYTA (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder [Press release].

Reviewed and updated by Justin Ray, MSN, PMHNP-BC — November 7, 2026

Take the first step towards medication and care that can help you feel better.

Schedule an appointment today to get diagnosed, receive a prescription, and continue your journey towards mental peace.

The lobby of South Chesapeake Psychiatry with seating and a front desk.